Effects of lovastatin and pravastatin on sleep efficiency and sleep stages
| Autor: | Kathy Tyson, Alexandros N. Vgontzas, Rocco L. Manfredi, Edward O. Bixler, Anthony Kales |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_specialty Internal medicine polycyclic compounds medicine Insomnia Humans Pharmacology (medical) Lovastatin Pravastatin Pharmacology Sleep disorder Sleep Stages business.industry nutritional and metabolic diseases medicine.disease Hydroxymethylglutaryl-CoA reductase Sleep in non-human animals Substance Withdrawal Syndrome Endocrinology Anesthesia Female lipids (amino acids peptides and proteins) Sleep onset medicine.symptom Sleep business medicine.drug |
| Zdroj: | Clinical Pharmacology and Therapeutics. 50:730-737 |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | The effects on sleep of two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (40 mg lovastatin and 40 mg pravastatin) were evaluated in 12 normal subjects in a double-blind placebo-controlled sleep laboratory study. Subjects were randomly assigned to each of two parallel groups (lovastatin and pravastatin). Each parallel-group protocol consisted of 22 consecutive nights including 4 placebo-baseline nights, 2 weeks of drug administration, and 4 placebo-withdrawal nights. Lovastatin did not disturb sleep initially (nights 5 through 7) but, with continued administration (nights 16 through 18), it significantly and markedly increased wake time after sleep onset and stage 1 sleep compared with baseline. By contrast, pravastatin was not associated with sleep disturbance either initially or with continued use. Neither drug caused any sleep disturbance after withdrawal. Lovastatin's sleep disturbing effects with continued administration are attributed to its high degree of lipophilicity in contrast with the hydrophilicity of pravastatin. Clinical Pharmacology and Therapeutics (1991) 50, 730–737; doi:10.1038/clpt.1991.213 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text